: Employer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds 

Many employers hold off on coverage of Wegovy and similar drugs amid cost concerns and the prospect of cheaper options down the road

Previous post Market Extra: Michael Burry of ‘Big Short’ fame is betting against high-flying semiconductor stocks
Next post How Disney can save the Marvel Cinematic Universe